UNASSIGNED: Here, we report a female patient with metastatic lung adenocarcinoma harboring LMO7-ALK (L15, A20) rearrangement revealed by NGS. The patient received crizotinib as first-line treatment and has achieved partial response with a progression-free survival over 1 year.
UNASSIGNED: We firstly found that the satisfactory response to crizotinib verified the oncogenic activity of LMO7-ALK fusion. Great progression and wide application of NGS facilitate the findings of rare fusion types.
■这里,我们报告1例女性转移性肺腺癌患者,NGS显示LMO7-ALK(L15,A20)重排.患者接受克唑替尼作为一线治疗,并已获得部分缓解,无进展生存期超过1年。
■我们首先发现对克唑替尼的满意反应证实了LMO7-ALK融合的致癌活性。NGS的巨大进步和广泛应用促进了罕见融合类型的发现。